<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3853">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056755</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719X2402</org_study_id>
    <nct_id>NCT03056755</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant</brief_title>
  <acronym>BYLieve</acronym>
  <official_title>A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+,
      HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6
      treatment with an aromatase inhibitor (AI) or fulvestrant
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2017</start_date>
  <completion_date type="Anticipated">March 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase II, multicenter, open-label, two-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in patients with HR+, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor whose disease has progressed on or after CDK 4/6 inhibitor containing treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who are alive without disease progression</measure>
    <time_frame>Date of first dose to approximately 6 months</time_frame>
    <description>Assess the percentage of patients without disease progression based on local investigator assessment per RECIST in cohort A and cohort B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) for each cohort</measure>
    <time_frame>date of first dose to up to approximately 25 months</time_frame>
    <description>PFS is defined as the time from the date of first dose of study medication to the date of the first documented progression or death due to any cause occurring in the study. PFS will be assessed based on local investigator's assessment according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) on next line treatment PFS2) for each cohort</measure>
    <time_frame>Date of first dose to date of first documented progression up to approximately 25 months</time_frame>
    <description>Progression free survival (PFS) on next line treatment (PFS2) is defined as time from the date of first dose of study medication to the date of first documented progression on next-line therapy or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants Overall response rate (ORR) for each cohort</measure>
    <time_frame>Date of first dose and up to approximately 25 months</time_frame>
    <description>ORR is defined as the percentage of participants with best overall response (BOR) of CR or partial response (PR), as per local investigator's assessment and according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical benefit rate (CBR) for each cohort</measure>
    <time_frame>Date of first dose and up to approximately 25 months</time_frame>
    <description>CBR is defined as the percentage of participants with a best ORR of complete response (CR) or partial response (PR) or an overall lesion response of stable disease (SD) or Non-CR/ Non-PD lasting ≥ 24 weeks based on local investigator's assessment according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Date of first documented response to first documented progression or death up to approximately 25 months</time_frame>
    <description>Duration of Response is the time from the date of first documented response (confirmed CR or PR) to the date of first documented progression or death due to underlying cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>alpelisib + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received any CDK 4/6 inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib + fulvestrant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alpelisib + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib + letrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpelisib</intervention_name>
    <description>300 mg; oral; once daily</description>
    <arm_group_label>alpelisib + fulvestrant</arm_group_label>
    <arm_group_label>alpelisib + letrozole</arm_group_label>
    <other_name>BYL719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>500 mg; intramuscular injection on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter</description>
    <arm_group_label>alpelisib + fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>2.5 mg; oral; once daily</description>
    <arm_group_label>alpelisib + letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient is male or female 18 years or older

          -  Patient is identified PIK3CA mutant status

          -  Patient has confirmed HER2-negative advanced breast cancer (aBC)

          -  Patient must be diagnosed with aBC with documented progression on or after CDK 4/6
             treatment (adjuvant or metastatic setting)

          -  Patient has histological and/or cytological confirmed ER+ and/or PgR+ aBC

          -  Patient has either measurable disease per RECIST v1.1 or at least one predominantly
             lytic bone lesion must be present

          -  ECOG function of greater or equal to 2

          -  Patient has adequate bone marrow function

          -  Patient has adequate liver and renal function

        Exclusion Criteria:

          -  patient has received prior treatment with any PI3K inhibitors

          -  patient with clinically manifest diabetes mellitus, or documented steroid induced
             diabetes mellitus

          -  Patient has a concurrent malignancy or malignancy within 3 years of study screening
             period, with the exception of adequately treated, basal or squamous cell carcinoma,
             non-melanoma skin cancer or curatively resected cervical cancer

          -  Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation
             ≤ 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from
             related side effects of such therapy

          -  History of acute pancreatitis within 1 year of screening or past medical history of
             pancreatitis

          -  Bilateral diffuse lymphangitis carcinomatosis

          -  Patients with central nervous system (CNS) involvement unless they meet ALL of the
             following criteria:

               -  At least 4 weeks from prior therapy completion (including radiation and/or
                  surgery) to starting the study treatment

               -  Clinically stable CNS tumor at the time of screening untreated or without
                  evidence of progressions for at least 4 weeks after treatment as determined by
                  clinical examination and brain imaging (MRI or CT) during screening period and
                  stable low dose of steroids for 2 weeks prior to initiating study treatment

          -  Patient with severe liver impairment (Child Pugh score B/C

          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of the study drugs

          -  Patient has documented pneumonitis which is active and requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>February 15, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced breast cancer</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>CDK 4/6 inhibitor</keyword>
  <keyword>fulvestrant</keyword>
  <keyword>letrozole</keyword>
  <keyword>HR+</keyword>
  <keyword>HER-negative</keyword>
  <keyword>post menopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
